Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies-Reference-Cited by-同舟云学术

Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies

Published:2018-11-07 Issue:1 Volume:7 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Jacot Terry A.¹,Clark Meredith R.¹²,Adedipe Oluwatosin E.¹,Godbout Susan¹,Peele Abby G.¹,Ju Susan¹²,Schwartz Jill L.¹²,Thurman Andrea R.¹,Doncel Gustavo F.¹²

Affiliation:

1. Eastern Virginia Medical SchoolCONRAD601 Colley Avenue23507NorfolkVAUSA

2. CONRAD1911 North Fort Meyer Drive22209ArlingtonVAUSA

Funder

U.S. President’s Emergency Plan for AIDS Relief

United States Agency for International Development

Eastern Virginia Medical School

Bill & Melinda Gates Foundation

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1186/s40169-018-0213-6

Reference34 articles.

1. Defining success with HIV pre-exposure prophylaxis

2. An Overview of Antiretroviral Pre-Exposure Prophylaxis of HIV Infection

3. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women

4. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women

5. Preexposure Prophylaxis for HIV Infection among African Women

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya;Frontiers in Reproductive Health;2023-06-13

2. Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study;PLOS ONE;2022-10-10

3. Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration;JAIDS Journal of Acquired Immune Deficiency Syndromes;2022-01-01

4. The use of objective adherence measures targeting four placebo microbicide delivery forms in the Quatro Clinical Crossover Study;Clinical and Translational Discovery;2021-10

5. The ins and outs of drug-releasing vaginal rings: a literature review of expulsions and removals;Expert Opinion on Drug Delivery;2020-08-09